Experts discuss best practices for improving patient adherence to hemophilia A therapies, including addressing adherence issues and patient engagement.
Robert Sidonio Jr, MD, MSc, discusses patient-centered therapy choices, highlighting the diverse options and considerations for hemophilia A treatment.
When Stormy Johnson's young son started bleeding heavily days after a routine surgery, she took him to the emergency department. Years later, the McDonough, Georgia, mother learned that she, too, had the same bleeding disorder.
Share this article
Share this article
ATLANTA, May 28, 2021 /PRNewswire/ Dr Robert Sidonio and Dr Carmen Escuriola-Ettingshausen have announced that MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) has commenced patient enrollment in the US.
MOTIVATE is a multicenter, investigator-initiated study aiming to capture different approaches used for the management of patients with hemophilia A and inhibitors. It is registered as a non-interventional study in the US (NCT04023019) and as a low-interventional, pragmatic trial in Europe (EudraCT No. 2019-003427-38).
Dr Sidonio, Coordinating Investigator of the study for the US and Canada, commented that We are very excited that patient enrollment in MOTIVATE has begun in the US. The data being collected will be invaluable in progressing our understanding of the efficacy and safety of different therapeutic regimens, bringing us closer to our goal of improving the standard of care for hemophilia A patients wit